Bloomberg reports the obesity drug market is expected to reach as much as $130 billion in annual sales by 2030.

Aldeyra's reproxalap faced an FDA setback but showed positive trial results, leading to a resubmitted NDA. Click here to find ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

In a report released today, Mohit Bansal from Wells Fargo maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of ...

Pfizer reacts to Donald Trump’s tariff threats on big pharma, another regulatory meeting is canceled under RFK Jr., AbbVie ...

Bank of America raised AbbVie’s price target from $200 to $223 while maintaining a neutral rating. Other analysts have also ...

AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra's obesity drug. AI takes center stage at HIMSS ...

The stock's fall snapped a three-day winning streak.

Cosmetic drugmaker Evolus reported a fourth-quarter profit versus a year-ago loss on Tuesday, on strong demand for its wrinkle treatment Jeuveau which competes with Botox.

The Trump administration is engaged in a effort to slash the federal government workforce. Military veterans make up nearly a ...

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...

Buying $1000 In ABBV: If an investor had bought $1000 of ABBV stock 5 years ago, it would be worth $2,381.00 today based on a price of $212.17 for ABBV at the time of writing.